Gentian Violet Treatment for Hidradenitis Suppurativa

Effects of Gentian Violet Treatment on Patients With Hidradenitis Suppurativa

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04388163

Enrollment

Registered

2020-05-14

Start date

2025-08-31

Completion date

2026-12-31

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa

Keywords

HS, Gentian Violet, nonsurgical treatment

Brief summary

This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey responses and quantitative changes in skin appearance.

Detailed description

Hidradenitis suppurativa (HS) is a chronic disease of the folliculopilosebaceous unit, often found in intertriginous areas of the body. The pain and impairment of HS leads patients to report a decreased quality of life, even in comparison to other debilitating cutaneous disease states. Pharmalogic management of HS can vary from topical antibiotics or intralesional corticosteroids for mild cases to immunosuppressants and biologic agents in refractory cases. Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration. It is our hypothesis that gentian violet will help minimize skin trauma in sites of active HS to promote improved wound healing and quality of life.

Interventions

DRUGGentian Violet

Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Patients must have active HS, be willing to undergo one application of HS, and agree to follow-up in one month.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Skin's Redness	baseline pre-treatment	Subjects rate site redness on a scale from 1 (no redness) to 5 (severe redness)
Skin's Drainage	baseline pre-treatment	Subjects rate skin drainage at treatment site on a scale from 1 (no drainage) to 5 (severe drainage)
Skin's Pain	baseline pre-treatment	Subjects rate skin pain at treatment site on a scale from 1 (no pain) to 5 (severe pain)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026